Tablets & Capsules

TC0717

Issue link: https://www.e-digitaleditions.com/i/845331

Contents of this Issue

Navigation

Page 15 of 57

CoQ10. This ANI is an endogenous cellular anti-oxidant that is vital for maintaining human health. It is a supplement used by people with various disease states, including dia- betes and neurodegenerative disorders [7]. To improve its solubility, Agrawal et al. formulated CoQ10 in a series of SENDS and loaded the individual pre-concentrates onto a silica carrier. Theses formulations were evaluated for dissolu- tion and hepatoprotection against pure CoQ10. All of the Agrawal SENDS formulations—comprising a primary solubilizer, emulsifier, surfactant, and co- surfactant—underwent emulsification to micro-emulsions (globule size of less than 200 nanometers) upon contact with an aqueous environment. The SENDS formulations attained complete dissolution of the CoQ10 in approxi- mately 30 minutes, while the pure ANI exhibited no dis- solution in the aqueous media. Additionally, the SENDS formulations provided better hepatoprotection than pure CoQ10, according the results of a CCl4 hepatic chal- lenge, as is demonstrated by the reduction in serum ala- nine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP). See Figure 2. This result is indicative of better bioavailability and therapeutic 14 July 2017 Tablets & Capsules Figure 3 Mean plasma concentrations of vitamin E [8] Notes: Results show plasma concentration (± SEM, n = 8) of gamma tocopherol as a function of time following oral administration of vitamin E (400 IU) in form of self-emulsifying preparation and softgel capsule after subtraction of endogenous vitamin E from each subject. Table 1 Pharmacokinetic parameters following vitamin E administration [8] Figure 4 Plasma concentration of quercetin after a single dose of a SENDS formulation and a free quercetin formulation [9] Figure 5 Nephroprotective effect markers after cyclosporine A challenge [9] Notes: CyA = Cyclosporine A P-QT-SEDDS-50 = Prophylactic quercetin SENDS formulation 50 mg/kg dose T-QT-SEDDS-50 = Therapy quercetin SENDS formulation 50 mg/kg dose P-free QT-50 = Prophylactic free quercetin formulation 50 mg/kg dose T-free QT-50 = Therapy free quercetin formulation 50 mg/kg dose P-free-100 = Prophylactic free quercetin formulation 100 mg/kg dose T-free-100 = Therapy free quercetin formulation 100 mg/kg dose Figure 6 Cardioprotective effect markers after doxorubicin challenge [9] Notes: Dox = Doxorubicin P-QT-SEDDS-50 = Prophylactic quercetin SENDS formulation 50 mg/kg dose T-QT-SEDDS-50 = Therapy quercetin SENDS formulation 50 mg/kg dose P-free QT-50 = Prophylactic free quercetin formulation 50 mg/kg dose T-free QT-50 = Therapy free quercetin formulation 50 mg/kg dose P-free-100 = Prophylactic free quercetin formulation 100 mg/kg dose T-free-100 = Therapy free quercetin formulation 100 mg/kg dose Self-emulsifying preparation Softgel 0 5 10 15 20 25 30 35 Time (h) Concentration (µg/ml) 7 6 5 4 3 2 1 0 QT-SEDDS = quercetin SENDS formulation Free QT = free quercetin formulation 1600 1400 1200 1000 800 600 400 200 0 0 10 20 30 40 50 60 70 80 Time (h) Plasma conentration (ng/ml) Serum creatinin level (mg/dl) Serum BUN level (%) Serum CK-MB level (U/L) Serum LDH level (U/L) Control Free P-QT- T-QT- P-free T-free P-free T-free CyA SEDDS-50 SEDDS-50 QT-50 QT-50 -100 -100 Control Free P-QT- T-QT- P-free T-free P-free T-free CyA SEDDS-50 SEDDS-50 QT-50 QT-50 -100 -100 Control Free P-QT- T-QT- P-free T-free P-free T-free Dox SEDDS-50 SEDDS-50 QT-50 QT-50 -100 -100 Control Free P-QT- T-QT- P-free T-free P-free T-free Dox SEDDS-50 SEDDS-50 QT-50 QT-50 -100 -100 1.4 1.2 1 0.8 0.6 0.4 0.2 0 50 40 30 20 10 0 80 70 60 50 40 30 20 10 0 600 500 400 300 200 100 0 Subject Softgel Self-emulsifying preparation C max (µg/ml) T max (h) AUC 0 -∞ (h • µg/ml) t 1/2 (h) C max (µg/ml) T max (h) AUC 0 -∞ (h • µg/ml) t 1/2 (h) 1 7.4 10.0 254.9 20.4 7.6 5.0 275.3 22.6 2 1.0 8.0 10.0 15.4 3.8 10.0 133.2 18.6 3 3.7 14.0 98.6 14.3 6.3 7.0 224.5 22.1 4 2.1 14.0 61.8 20.9 5.5 10.0 196.4 23.3 5 3.3 14.0 117.2 18.6 7.4 10.0 280.3 21.9 6 1.0 14.0 36.1 14.8 7.5 7.0 194.5 14.1 7 2.0 14.0 71.7 21.3 3.7 5.0 118.6 19.0 8 3.5 8.0 106.4 18.5 10.7 6.0 262.6 20.1 Mean 3.0 12.0 94.6 18.0 6.6 7.5 210.7 20.2 SD ± 2.1 2.8 80.0 2.8 2.3 2.2 63.0 3.0

Articles in this issue

Archives of this issue

view archives of Tablets & Capsules - TC0717